Is Modified GRF 1-29 legal in Australia?

Sold as CJC-1295 without DAC, which is a contradiction: the DAC is what makes a molecule CJC-1295. The human trial everyone quotes, 2 to 10 fold higher growth hormone for 6 days or more with a half-life of 5.8 to 8.1 days, was run on the DAC form. No human trial of the version without the DAC has been located.

Start with the naming, because the naming is the error. The 2005 paper that created CJC-1295 tested three maleimido derivatives of human growth hormone releasing factor 1-29 designed to bond to the free thiol on cysteine 34 of serum albumin.

Mechanism: A growth hormone releasing hormone analogue acting at the GHRH receptor on anterior pituitary somatotrophs to trigger growth hormone release, which raises IGF-1 downstream. The tetrasubstitution of the native GRF 1-29 sequence resists dipeptidyl peptidase IV cleavage, extending the peptide's survival in plasma from minutes to somewhat longer, but it does not confer albumin binding.

Regulatory history: Not approved for any indication and not evaluated. Sermorelin, the unmodified GRF 1-29, was an approved medicine in the United States and is no longer marketed in its original form. Tesamorelin, a different GHRH analogue, is approved for HIV-associated lipodystrophy.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Modified GRF 1-29 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.